CHChang Huang

Chang Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chang Huang has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Cameron Allen

    Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health

    2 shared publications
  • Gabrielle Grubbs

    Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20993, USA

    2 shared publications
  • Ming Zhao

    Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health

    2 shared publications
  • Motoshi Suzuki

    Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health

    2 shared publications
  • Peter D. Sun

    Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health

    2 shared publications
  • Youri Lee

    Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20993, USA

    2 shared publications

Latest Publications

  • Open Access

    Vaccination protects against COVID-associated pulmonary fibrin deposition

    by Joanna Ireland, David Myers, Chang Huang, Cameron Allen, Gwynne Roth, Zhongcheng Zou, Ming Zhao, Motoshi Suzuki, Lisa Olano, Joshua Tan, et al.

    Understanding the protective mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines against severe COVID is important for therapeutic development to mitigate disease-associated lung pathologies. Here, we investigated the association between vaccination and the disease severity with a particular emphasis on viral-induced pulmonary fibrin formation in 43 COVID individuals. While COVID vaccination reduced the disease severity in this cohort, their plasma coagulation indices, including prothrombin time (PT), partial thromboplastin time (PTT), and D-dimer concentrations, remain unchanged between the vaccinated and non-vaccinated individuals. In contrast, vaccination lowered pulmonary inflammatory and coagulation signatures, reduced fibrinogen concentrations, and prevented prothrombin activation in bronchoalveolar lavage fluid (BALF), such that no viral-induced fibrin was observed in the vaccinated BALF. The formation of viral-induced fibrin correlated with the disease severity and was observed in non-vaccinated BALF samples containing high concentrations of fibrinogen and prothrombin, suggesting vaccination protected against the viral-induced pulmonary fibrin formation. Our finding highlights the use of pulmonary rather than plasma fibrinogen levels as a risk indicator for severe COVID disease. IMPORTANCE: Understanding the protective mechanism of COVID-19 vaccines against the severity of the disease is important for therapeutic development, and thus, subject to intense investigation. Here, we studied a cohort of 43 COVID patients based on their vaccination status. We showed that (i) COVID disease severity is associated with the formation of SARS-CoV-2-induced pulmonary fibrin, (ii) vaccination protected against severe COVID disease by reducing infiltration of coagulants, preventing prothrombin activation and fibrin deposition in infected lungs, and (iii) plasma coagulation indices are not useful indicators for fibrin deposition in infected lungs. Rather, the level of pulmonary fibrinogen provides an informative indicator for COVID-associated coagulation in lung.


  • Open Access

    SARS-CoV-2 infection of human lung epithelial cells induces TMPRSS-mediated acute fibrin deposition

    by Rachel Erickson, Chang Huang, Cameron Allen, Joanna Ireland, Gwynne Roth, Zhongcheng Zou, Jinghua Lu, Bernard A. P. Lafont, Nicole L. Garza, Beniah Brumbaugh, et al.

    Severe COVID-associated lung injury is a major confounding factor of hospitalizations and death with no effective treatments. Here, we describe a non-classical fibrin clotting mechanism mediated by SARS-CoV-2 infected primary lung but not other susceptible epithelial cells. This infection-induced fibrin formation is observed in all variants of SARS-CoV-2 infections, and requires thrombin but is independent of tissue factor and other classical plasma coagulation factors. While prothrombin and fibrinogen levels are elevated in acute COVID BALF samples, fibrin clotting occurs only with the presence of viral infected but not uninfected lung epithelial cells. We suggest a viral-induced coagulation mechanism, in which prothrombin is activated by infection-induced transmembrane serine proteases, such as ST14 and TMPRSS11D, on NHBE cells. Our finding reveals the inefficiency of current plasma targeted anticoagulation therapy and suggests the need to develop a viral-induced ARDS animal model for treating respiratory airways with thrombin inhibitors.


  • Open Access

    Systemic and mucosal immune profiling in asymptomatic and symptomatic SARS-CoV-2–infected individuals reveal unlinked immune signatures

    by Supriya Ravichandran, Gabrielle Grubbs, Juanjie Tang, Youri Lee, Chang Huang, Hana Golding, Surender Khurana

    Mucosal SARS-CoV-2 immune profiles are divergent in asymptomatic versus symptomatic SARS-CoV-2–infected individuals.


  • Open Access

    Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern

    by Juanjie Tang, Youri Lee, Supriya Ravichandran, Gabrielle Grubbs, Chang Huang, Charles B. Stauft, Tony Wang, Basil Golding, Hana Golding, Surender Khurana